Albion Ventures LLP, partnership with UCL Business (UCLB) has made a GBP1 million investment in Abcodia a company engaged in the validation and discovery of molecular biomarkers for disease diagnosis and screening. The investment will help develop Abcodia’s visionary plans which could transform the way that life-threatening diseases are diagnosed.
This investment builds on Albion’s established reputation as an investor in the healthcare sector, including previous investments in diagnostic technologies. Companies already in the portfolio include Mirada Medical, Vivacta, Dexela and Dysis Medical. The Abcodia investment compliments previous asset-backed investments such as Oakland Care Home made last year, to create a diversified healthcare portfolio balancing high return investments with low risk asset backed investments.
Abcodia benefits from having access to a unique serum collection licensed from the University College London (UCL), one of the world’s leading research-led universities and through global partnerships. Abcodia aims to make groundbreaking discoveries and improve the diagnosis of many common life-threatening and debilitating diseases, including the major cancers – colon, lung, pancreatic – as well as other conditions such as diabetes, osteoporosis and rheumatoid arthritis.
Andrew Elder (pictured), Partner, Albion Ventures, says: “Healthcare is an important theme within Albion’s portfolio and a significant area of opportunity for investment growth. Abcodia is an attractive investment for us given its unique position in the global diagnostic market, which is seeing a rapid growth due to the demand for effective diagnostics for disease screening and personalised medicine.”